Aspirin induces its anti-inflammatory effects through its specific binding to phospholipase A2: Crystal structure of the complex formed between phospholipase A2 and aspirin at 1.9 Å resolution

Phospholipase A2 is potentially an important target for structure-based rational drug design. In order to determine the involvement of phospholipase A2 in the action of non-steroidal anti-inflammatory drugs (NSAIDs), the crystal structure of the complex formed between phospholipase A2 and aspirin has been determined at 1.9 Å resolution. The structure contains 915 protein atoms, 1 calcium ion, 13 atoms of aspirin and 105 water molecules. The observed electron density of the aspirin molecule in the structure was of very high quality thus allowing the precise determination of its atomic coordinates leading to the clear description of its interactions with the enzyme. The structure of the complex clearly shows that aspirin is literally embedded in the hydrophobic environment of PLA2. It is so placed in the substrate binding channel that it forms several important attractive interactions with calcium ion, His 48 and Asp 49. Thus, the structure of the complex clearly shows that aspirin occupies a favourable place in the specific binding site of PLA2. The binding studies have shown that acetyl salicylate (aspirin) binds to PLA2 enzyme specifically with a dissociation constant of 6.4×10−6 M. The structural details and binding data suggest that the inhibition of PLA2 by aspirin is of pharmacological significance and part of its anti-inflammatory effects may be due to its binding with PLA2.

[1]  R. Sperling Eicosanoids in rheumatoid arthritis. , 1995, Rheumatic diseases clinics of North America.

[2]  C. Betzel,et al.  Structural basis of phospholipase A2 inhibition for the synthesis of prostaglandins by the plant alkaloid aristolochic acid from a 1.7 A crystal structure. , 2002, Biochemistry.

[3]  M. Gelb,et al.  Crystal structure of bee-venom phospholipase A2 in a complex with a transition-state analogue , 1990, Science.

[4]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[5]  D. Dewitt Prostaglandin endoperoxide synthase: regulation of enzyme expression. , 1991, Biochimica et biophysica acta.

[6]  Sujata Sharma,et al.  Design of specific peptide inhibitors for group I phospholipase A2: structure of a complex formed between phospholipase A2 from Naja naja sagittifera (group I) and a designed peptide inhibitor Val-Ala-Phe-Arg-Ser (VAFRS) at 1.9 A resolution reveals unique features. , 2003, Biochemistry.

[7]  J.-P. Wery,et al.  Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2 , 1995, Nature Structural Biology.

[8]  G. N. Ramachandran,et al.  Conformation of polypeptides and proteins. , 1968, Advances in protein chemistry.

[9]  A. Szabó,et al.  Surface plasmon resonance and its use in biomolecular interaction analysis (BIA). , 1995, Current opinion in structural biology.

[10]  M. Feldman,et al.  Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. , 1998, The American journal of medicine.

[11]  I. Pavord,et al.  Induced sputum eicosanoid concentrations in asthma. , 1999, American journal of respiratory and critical care medicine.

[12]  E. Granström Prostaglandin biochemistry, pharmacy and physiological function. The prostaglandins, thromboxanes and leukotrienes. , 1983, Acta obstetricia et gynecologica Scandinavica. Supplement.

[13]  D. Velmurugan,et al.  Crystal structures of the free and anisic acid bound triple mutant of phospholipase A2. , 2003, Journal of molecular biology.

[14]  J. J. Rosa,et al.  Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate. , 1993, Science.

[15]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[16]  M. Perbandt,et al.  Crystal Structure of a Complex Formed between a Snake Venom Phospholipase A2 and a Potent Peptide Inhibitor Phe-Leu-Ser-Tyr-Lys at 1.8 Å Resolution* , 2002, The Journal of Biological Chemistry.

[17]  L. Nieba,et al.  Competition BIAcore for measuring true affinities: large differences from values determined from binding kinetics. , 1996, Analytical biochemistry.

[18]  P. Majerus,et al.  The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. , 1975, The Journal of clinical investigation.

[19]  Daniel Picot,et al.  The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase , 1995, Nature Structural Biology.

[20]  P. Sigler,et al.  Crystal structure of cobra-venom phospholipase A2 in a complex with a transition-state analogue. , 1990, Science.

[21]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[22]  S S Abdel-Meguid,et al.  High-resolution X-ray crystallography reveals precise binding interactions between human nonpancreatic secreted phospholipase A2 and a highly potent inhibitor (FPL67047XX). , 1996, Journal of medicinal chemistry.

[23]  M. Sundaralingam,et al.  Crystal structure of the complex of bovine pancreatic phospholipase A2 with the inhibitor 1-hexadecyl-3-(trifluoroethyl)-sn-glycero-2-phosphomethanol,. , 1997, Biochemistry.

[24]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[25]  C. Betzel,et al.  Design of specific peptide inhibitors of phospholipase A2: structure of a complex formed between Russell's viper phospholipase A2 and a designed peptide Leu-Ala-Ile-Tyr-Ser (LAIYS). , 2002, Acta crystallographica. Section D, Biological crystallography.

[26]  K. Sharp,et al.  Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons , 1991, Proteins.

[27]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[28]  C. Betzel,et al.  First structural evidence of a specific inhibition of phospholipase A2 by alpha-tocopherol (vitamin E) and its implications in inflammation: crystal structure of the complex formed between phospholipase A2 and alpha-tocopherol at 1.8 A resolution. , 2002, Journal of molecular biology.

[29]  P. Elsbach,et al.  Low concentrations of indomethacin inhibit phospholipase A2 of rabbit polymorphonuclear leukocytes. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.